Intracranial PrEssure Time dOse (ImPETO)

Launched by UNIVERSITY OF MILANO BICOCCA · Jul 1, 2020

Keywords

ClinConnect Summary

The ImPETO trial is studying how continuous monitoring of intracranial pressure (ICP) can help doctors understand patient outcomes better for people with serious brain injuries, such as traumatic brain injury or bleeding in the brain. The trial uses a new device called the Integra CereLink ICP monitor, which provides real-time data about pressure in the brain. Researchers want to see if tracking a specific measurement called Pressure Time Dose (PTD) can help predict whether patients will do well or poorly after their injury.

To participate in this study, individuals need to be between the ages of 18 and 80 and must have been diagnosed with an acute brain injury that requires ICP monitoring. This includes conditions like hemorrhagic strokes or traumatic brain injuries. If eligible, patients will have their ICP monitored closely using the Integra device, and researchers will analyze the data to find meaningful patterns that could improve care for future patients. It's important to note that only those with the specific monitoring equipment will be able to take part in this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged within 18 and 80 years;
• • Diagnosed of an acute brain injury (ABI) for hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury;
• • ICP monitoring started for clinical indication and accordingly to local policies
• • ICP device connected to the Integra CereLink ICP monitor.
• Exclusion Criteria:
• • ICP monitoring not inserted
• • No availability of the Integra CereLink ICP monitor.